Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development 
How Braden Business Systems Use Auvik SaaS Management
to Identify, Secure, and Manage SaaS Sprawl About Braden Business Systems & Jon Fitzryk Since 1989, Braden Business Systems has...
Efficient Network Management: A Dive into Auvik Network Management’s Robust Features
In today's fast-paced digital world, efficient and effective network management has become more important than ever. With businesses relying heavily...
Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development
Appointment Follows US$6.5 Million Strategic Financing and Strengthens Board Leadership Alongside David Adelman, Kevin Mayer, Lee Applbaum and James McRobertsVancouver,...
ANGEL Brings Professional Coffee Water Solutions to the 2026 San Francisco Coffee Festival
SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- ANGEL served as the Official Water Partner of the 2026 San Francisco...
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a...
Bavarian Nordic Launches Next Tranche of DKK 750 Million Share Buy-Back Program
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the share buy-back...
Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress...
Henrik Juuel to Step Down as Chief Financial Officer of Bavarian Nordic in 2027
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that Henrik Juuel has informed the Board...
HoneyPezil Announced New Advanced HoneyPezil Memory Capsules To Brain Health Support for Adults Seeking Everyday Cognitive Wellness in USA 2026.
Honey Pezil introduces a brain health supplement formulated to support memory focus and cognitive wellness as part of a balanced...
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and...
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models...
Sienna Reports Third Quarter 2026 Financial Results and Continues Platform Growth
MARKHAM, Ontario, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced...
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home AdministrationTOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE)...
Windward Bio Announces Pricing of Initial Public Offering
BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing...
VitalHub Reports Third Quarter 2026 Results
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 14% YoY to $107.2 millionTotal Revenue flat YoY at $31.9 millionAdjusted EBITDA⁽¹⁾ up 20% YoY...
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome)...
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Following reporting of results for the ELPIS II Phase 2b...
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 FDA...
YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
FDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001 TAIPEI, Taiwan, Nov. 12, 2026...
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half...
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027...
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLCCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) --...